Wall Street expects a year-over-year increase in earnings on higher revenues when Phibro Animal Health (PAHC) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on F ...

Growth Investing and Phibro Animal Health - Growth investors focus on stocks with above-average financial growth, which can deliver solid returns but carry higher risk and volatility [1] - The Zacks Growth Style Score helps identify cutting-edge growth stocks by analyzing real growth prospects beyond traditional attributes [2] - Phibro Animal Health (PAHC) is recommended by the Zacks system due to its favorable Growth Score and top Zacks Rank [2] Earnings Growth - Earnings growth is crucial for growth investors, with double-digit growth indicating strong prospects and potential stock price gains [4] - Phibro's historical EPS growth rate is 0 9%, but its projected EPS growth for this year is 36 1%, significantly higher than the industry average of 21 8% [5] Asset Utilization and Sales Growth - Phibro has an impressive asset utilization ratio (S/TA) of 1 07, meaning it generates $1 07 in sales per dollar of assets, compared to the industry average of 0 6 [6] - The company's sales are expected to grow 15 7% this year, outperforming the industry average of 5 3% [7] Earnings Estimate Revisions - Positive earnings estimate revisions are a strong indicator of near-term stock price movements [8] - Phibro's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate surging 0 3% over the past month [9] Conclusion - Phibro has earned a Growth Score of A and a Zacks Rank 2 due to its strong earnings estimate revisions and growth metrics [11] - This combination positions Phibro well for outperformance, making it an attractive option for growth investors [11]

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Z ...

Core Insights - The article compares Phibro Animal Health (PAHC) and Stryker (SYK) to determine which stock offers better value for investors [1] Valuation Metrics - PAHC has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while SYK has a Zacks Rank of 3 (Hold) [3] - PAHC's forward P/E ratio is 12.81, significantly lower than SYK's forward P/E of 26.27 [5] - PAHC's PEG ratio is 0.53, suggesting it is undervalued relative to its expected earnings growth, compared to SYK's PEG ratio of 2.44 [5] - PAHC has a P/B ratio of 3.24, while SYK's P/B ratio is 6.72, further indicating PAHC's relative undervaluation [6] - Based on these metrics, PAHC is rated with a Value grade of A, while SYK has a Value grade of C, highlighting PAHC as the superior value option [6]

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuati ...

Phibro Animal Health Corporation’s (PAHC) focus on advancing vaccine technologies is poised to drive growth in the upcoming quarters. The company’s global growth prospects look encouraging. Yet, adverse currency fluctuations and fierce competitive impacts are concerns for Phibro’s operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have rallied 82.8% compared with the industry’s 9.6% growth and the S&P 500 composite's 26.7% increase.The renowned animal health and mineral nutrition compan ...

Phibro Animal Health (PAHC) has seen impressive momentum in the past year, with its shares soaring 82.8%. It has significantly outperformed the 9.6% rise of the industry and the S&P 500 Composite’s 26.7% gain.Presently carrying a Zacks Rank #3 (Hold), the diversified animal health and mineral nutrition company is benefiting from the remarkable performance of the Animal Health business. Phibro is well-positioned to pursue global growth opportunities, while the resilience of the Mineral Nutrition arm is highl ...

Core Insights - Phibro Animal Health Corporation (PAHC) is experiencing growth in its Animal Health business, driven by advancements in vaccine technologies and a rebound in Mineral Nutrition and Performance Product sectors [1][4][9] - The company's shares have significantly outperformed the industry and the S&P 500 over the past year, with a 107.9% increase compared to the industry's 20.9% and the S&P 500's 32.4% [2] - Phibro's market capitalization stands at $872 million, and it has consistently surpassed earnings estimates, achieving an average surprise of 25.47% over the last four quarters [2] Phibro's Key Tailwinds - The Animal Health business is benefiting from increased demand for efficient food production due to natural resource scarcity, with key products like Medicated Feed Additives (MFAs) and vaccines driving growth [4] - The company reported a 14% year-over-year sales growth in the Animal Health segment for the fiscal first quarter, with vaccine net sales increasing by 22% [6][8] - Phibro has expanded its vaccine manufacturing capacity, including a new facility in Brazil for autogenous vaccines targeting swine, poultry, and aquaculture [7] Recovery in Other Segments - The Mineral Nutrition business grew by 5% year-over-year, supported by increased demand for trace minerals, while Performance Products saw a 27% increase in sales [9] - Adjusted EBITDA for these segments increased by 64%, prompting the company to raise its fiscal 2025 sales guidance [9] Macroeconomic Concerns - Phibro's operations are facing challenges from macroeconomic factors such as economic sanctions, supply chain disruptions, and inflationary pressures, which could impact profitability [11] - The cost of goods sold increased by 8.1% compared to the previous year [12] Estimate Trends - The Zacks Consensus Estimate for fiscal 2025 earnings per share has increased by 2.5% to $1.61, with revenue estimates at $1.18 billion, reflecting a 15.6% rise from the previous year [13]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill this potential is challenging [1] Group 1: Company Overview - Phibro Animal Health (PAHC) is currently recommended as a growth stock by the Zacks Growth Style Score system, which evaluates a company's real growth prospects beyond traditional metrics [2] - The company has a favorable Growth Score and a top Zacks Rank, indicating strong growth potential [2] Group 2: Earnings Growth - Historical EPS growth for Phibro is 0.9%, but projected EPS growth for this year is expected to be 35.5%, significantly higher than the industry average of 15.8% [4] Group 3: Asset Utilization - Phibro's asset utilization ratio (sales-to-total-assets ratio) is 1.07, indicating that the company generates $1.07 in sales for every dollar in assets, outperforming the industry average of 0.6 [5] Group 4: Sales Growth - The company's sales are projected to grow by 15.6% this year, compared to an industry average of 0% [6] Group 5: Earnings Estimate Revisions - The current-year earnings estimates for Phibro have been revised upward, with the Zacks Consensus Estimate increasing by 2.9% over the past month, indicating a positive trend in earnings estimate revisions [7] Group 6: Overall Positioning - Phibro has achieved a Zacks Rank of 2 and a Growth Score of B, positioning it well for potential outperformance in the growth stock category [9][11]